The Valley Desk

ArticleNeurology and therapyPublished

Cost Per Relapse Avoided for Ozanimod Versus Other Selected Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis in the United States

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Bristol Myers Squibb, University of Pennsylvania. Affiliation source

Publication record

Type
Article
Venue
Neurology and therapy
Published
Subject terms
Cost-effectiveness Analysis; Relapsing–remitting Multiple Sclerosis; Disease-modifying Therapies; Ozanimod
PubMed ID
37000386
PubMed Central ID
PMC10195930
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal